The Feasibility of Using Emerging Antibody-drug Conjugates for the Treatment of Small Cell Lung Cancer
DOI:
https://doi.org/10.61173/k8nzms05Keywords:
Antibody-drug conjugate (ADC), Small cell lung cancer (SCLC), DLL-3, SEZ6, K-citAbstract
Antibody-drug conjugate (ADC) consists of three parts: antibodies, linkers, and cytotoxic payloads. With the deepening of research on ADC, the potential therapeutic effects of ADC on SCLC have also been emphasized. This study aims to evaluate and introduce five novel ADCs targeting small cell lung cancer (SCLC) and explore their anti-tumor activity, cytotoxicity, application prospects and so on. The first ADC drug is rovalpituzumab tesirine(Rova-T), currently, Rova-T has entered Phase Ⅲ clinical trial. The second drug is ABBV-011, and a study found that a single dose of ABBV-011 can lead to significant dose-dependent tumor regression in LU64. The third drug is NN2101-DM1, which is found to exhibit anti-tumor activity in xenograft mouse models. The fourth drug is D3-GPC2-PBD ADC. A study treated mice carrying NCI-H526(H526) xenografts with D3-GPC2-PBD ADC and found that the drug can lead to robust and sustained tumor regression, significantly improving the survival rate of mice without any side effects. The fifth study was on ADC targeting junctional adhesion molecule 3 Gene (JAM3), which found that SCLC cell lines typically express high levels of JAM3. The study also found that knocking down JAM3 can inhibit the growth of SCLC cells. Although these five ADCs are in different clinical trial stages, they all have inhibitory effects on SCLC.
References
[1] Cui X, Song P, Zhang L. New Advances in the Treatment for Small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi, 2019, 22(6): 355-362.
[2] Megyesfalvi Z, Gay C M, Popper H, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin, 2023, 73(6): 620-652.
[3] Belluomini L, Sposito M, Avancini A, et al. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers (Basel), 2023, 15(22).
[4] Fu Z, Li Z, Han, S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther, 2022, 7(1): 93.
[5] Hafeez U, Parakh S, Gan H K, et al. Antibody-Drug Conjugates for Cancer Therapy. Molecules, 2020, 25(20).
[6] Wang Q, Gumus Z H, Colarossi C, et al. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thorac Oncol, 2023, 18(1): 31-46.
[7] Owen D H, Giffin M J, Bailis J M, et al. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol, 2019, 12(1): 61.
[8] Lahiri A, Maji A, Potdar P D, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer, 2023, 22(1): 40.
[9] Rudin C M, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers, 2021, 7(1): 3.
[10] Rudin C M, Pietanza M C, Bauer T M, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, openlabel, phase 1 study. Lancet Oncol, 2017, 18(1): 42-51.
[11] Wiedemeyer W R, Gavriyuk J, Schammel A, et al. ABBV- 011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. Mol Cancer Ther, 2022, 21(6): 986-998.
[12] Kim J O, Kim K H, Beak E J, et al. A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activatingmutant c-Kit-positive tumors. Mol Oncol, 2022, 16(6): 1290- 1308.
[13] Raman S, Buongervino S N, Lane M V, et al. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Rep Med, 2021, 2(7): 100344.
[14] Yamaguchi M, Hirai S, Idogawa M, et al. Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma. Exp Cell Res, 2023, 426(2): 113570.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
